PFE - Pfizer Sees Less Revenue From Covid-19 Treatments Stock Faces Headwinds Ahead Of Q1 Earnings | Benzinga
Pfizer Inc (NYSE:PFE) stock has declined significantly due to decreased revenue from its COVID-19 products.
The stock is down 34.61% over the past year, and 10.94% year-to-date.
While Pfizer’s dividend appears to be inexpensive, investors are noting significant risks facing the company ahead of first-quarter earnings on Wednesday.
Wall Street expects 49 cents in EPS and $13.09 billion in revenues as the company reports before market hours.
The stock sports a forward dividend yield of 6.55% currently.
Investors should also monitor management’s plans to reduce debt while maintaining the dividend. Being a pharmaceutical business, focus should also be on the company’s development pipeline to gauge the company’s potential trajectory.
Pfizer is a decent choice in healthcare, especially for those prioritizing current income and appreciating its competitive advantages and strong credit rating. However, the risk-reward balance is currently skewed towards caution.
Let’s look at what ...